???This merger, combined with our recent $12 million financing, provides BioSante with the funding required for the continued Phase III development of LibiGel for FSD and offers the potential to expand our product development portfolio with the addition of GVAX Immunotherapies,??? said Stephen M. Simes, BioSante??™s president and CEO. ???LibiGel remains the only pharmaceutical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women. We continue to believe that LibiGel can be the first product approved by the FDA for the common and unmet medical need of FSD. In addition, our company has had a long-standing interest in immunotherapy based on our proprietary vaccine adjuvant, BioVant?„?, and we look forward to future value-creating opportunities for stockholders based on Cell Genesys??™s technologies.???

???After reviewing various strategic alternatives, engaging in discussions with a number of other potential merger candidates and conducting extensive due diligence on BioSante??™s product development and business activities, our board of directors has voted unanimously to recommend a merger with BioSante,??? stated Stephen A. Sherwin, M.D., chairman and CEO of Cell Genesys.

???We believe that BioSante??™s lead product, LibiGel, represents a compelling near term product opportunity with significant upside potential. We also are impressed with BioSante??™s record of achievement including the recent launch of Elestrin?„? (estradiol gel) as well as their CaP nanotechnology platform which includes BioVant, a novel vaccine adjuvant with potential in immunotherapy,??? Dr. Sherwin continued.

biosantepharma